孟鲁司特和布地奈德治疗支气管哮喘的研究

目的探讨孟鲁司特和布地奈德治疗支气管哮喘的临床疗效。方法将102例轻、中度支气管哮喘患者随机分为4组：A组（24例）每次服用孟鲁司特10mg，每晚1次。B组（28例）每次吸入布地奈德400μg，每天2次。C组（24例）每次吸入布地奈德400μg，每天2次；加用孟鲁司特10mg，每晚1次。D组（26例）每次吸入布地奈德800μg，每天2次。结果4组治疗后气道反应性的组胺浓度（PC20）评价指标均明显增加，差异均有统计学意义（P〈0．05）。其中C组治疗后评价指标改善比其他各组更明显，差异有统计学意义（P〈0．05）。C组和D组治疗后肺功能指标均高于治疗前，差异有统计学意义（P〈0．05）；且改善情况优于A组和B组，差异均有统计学意义（P〈0．05）。结论孟鲁司特联合吸人布地奈德治疗轻、中度支气管哮喘效果显著，可减少肾上腺糖皮质激素用量。

Observation of the effect of montelukast and budesonide on bronchial asthma

Objective To assess the clinical effect of montelukast and budesonide on bronchial asthma. Methods 102 cases with mild to moderate bronchial asthma were randomly divided into 4 group. Montelukast was given （ oral dosage,10mg, once a day）in group A. Inhaled corticosteroid budesonide was given（400μg, once a day）in group B. Inhaled corticosteroid budesonide was given （400μg, once a day）, and Montelukast was given （ oral dosage, 10mg, once a day） in group C. Inhaled corticosteroid budesonide was given（800μg, once a day）in group D. Results After treatment,the airway responsiveness histamine concentration（PC20） were significantly higher, the differences were statistically significant（ P 〈 0.05 ）, the situation improved of group C was better than the other groups, the differences were statistically significant （ P 〈 0.05 ） ; The lun function of group C and group D were higher than before treatment, the differences were statistically siginficact （ P 〈 0.05 ）, and the stua- tian improved were better than group A and group B, the differences were statistically significant （ P 〈 0.05 ）. Conclusion Montelukast and budesonide could improve mild to moderate asthma in patients with dyspnea, cough, wheezing symptoms,lung function. It is a new type ofanti-inflammatory and anti-asthmatic drugs on bronchi-al asthma, with a good clinical value.